Phase I, double-blinded, placebo-controlled dosage escalation study of the safety and immunogenicity of adjuvanted and non-adjuvanted inactivated SARS coronavirus (SARS-CoV) vaccine administered by the intramuscular route.

Trial Profile

Phase I, double-blinded, placebo-controlled dosage escalation study of the safety and immunogenicity of adjuvanted and non-adjuvanted inactivated SARS coronavirus (SARS-CoV) vaccine administered by the intramuscular route.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 30 Nov 2012

At a glance

  • Drugs Aluminium hydroxide; Coronavirus vaccine
  • Indications Severe acute respiratory syndrome
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 05 Aug 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 12 May 2011 Planned end date changed from 1 Jan 2010 to 1 Jan 2012 as reported by ClinicalTrials.gov.
    • 26 Nov 2008 Checked against ClinicalTrials.gov record NCT00533741.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top